# OnCo record paper-wolf-geometry-mono-1-capmatinib-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-wolf-geometry-mono-1-capmatinib-nejm-2020" ;
  schema:name "Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer"@en ;
  schema:description "MET exon 14 skipping is found in 3 to 4 percent of lung cancers. Untreated patients given capmatinib responded 68 percent of the time; those already treated, 41 percent. Order of treatment mattered more than usual."@en ;
  schema:url <https://onco.cc/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2002787>, <https://pubmed.ncbi.nlm.nih.gov/32877583/>, <https://clinicaltrials.gov/study/NCT02414139> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2002787> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Wolf J, Seto T, Han JY, et al." ;
  onco:related <https://onco.cc/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/>, <https://onco.cc/key-papers/paper-cho-mariposa-amivantamab-lazertinib-nejm-2024/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/> ;
  onco:trials <https://onco.cc/trials/geometry-mono-1/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .